Table 1.
Clinical characteristics of the subjects.
| Group | IA | IT | IC | HC |
|---|---|---|---|---|
| No. of patients | 20 | 10 | 15 | 12 |
| Gender (M/F) | 14/6 | 6/4 | 5/10 | 8/4 |
| Age (years) | 28.00 (21.00–41.80) | 26.50 (3.80–34.70) | 36.00 (22.60–54.40) | 24.00 (21.30–34.40) |
| Hepatitis B virus (HBV) DNA (log10 copies/ml) | 8.40 (5.94–9.39) | 7.70 (5.55–8.70) | 0.00a (0.00–3.94) | ND |
| ALT (U/l) | 145.00 (70.60–295.30) | 22.00 (16.10–40.90) | 18.00 (10.60–33.40) | 15.00 (12.00–27.70) |
| AST (U/l) | 90.50 (48.10–225.40) | 24.50 (19.30–34.50) | 25.00 (16.40–35.00) | 22.00 (12.00–31.20) |
| HBsAg positive | 20 | 10 | 12 | 0 |
| Anti-HBs positive | 0 | 0 | 1 | 6 |
| Hepatitis B virus e antigen positive | 20 | 5 | 5 | 0 |
| Anti-Hbe positive | 0 | 5 | 7 | 0 |
| Anti-HBc positive | 20 | 10 | 15 | 0 |
| CXCL13 (pg/ml) | 67.18 (46.77–180.51) | 42.30 (23.92–85.69) | 31.93 (17.46–98.42) | 32.33 (13.69–49.90) |
Data were shown as median and 10–90% percentile.
a11 IC had undetectable HBV DNA.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HC, healthy control; IA, immune activation; IC, inactive carrier; IT, immune tolerance; ND, not determined.